CN105764527A - 新b细胞细胞因子的鉴定 - Google Patents

新b细胞细胞因子的鉴定 Download PDF

Info

Publication number
CN105764527A
CN105764527A CN201480063597.2A CN201480063597A CN105764527A CN 105764527 A CN105764527 A CN 105764527A CN 201480063597 A CN201480063597 A CN 201480063597A CN 105764527 A CN105764527 A CN 105764527A
Authority
CN
China
Prior art keywords
cells
cell
lymphoma
disease
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480063597.2A
Other languages
English (en)
Chinese (zh)
Inventor
艾伯特·兹洛特尼克
彼得·海维兹
万·菲·鲁
阿曼达·M·伯克哈特
伊琳娜·奥谢什
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN105764527A publication Critical patent/CN105764527A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
CN201480063597.2A 2013-11-20 2014-11-20 新b细胞细胞因子的鉴定 Pending CN105764527A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361906855P 2013-11-20 2013-11-20
US61/906,855 2013-11-20
PCT/US2014/066712 WO2015077506A2 (en) 2013-11-20 2014-11-20 Identification of a novel b cell cytokine

Publications (1)

Publication Number Publication Date
CN105764527A true CN105764527A (zh) 2016-07-13

Family

ID=53180393

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480063597.2A Pending CN105764527A (zh) 2013-11-20 2014-11-20 新b细胞细胞因子的鉴定

Country Status (8)

Country Link
US (2) US20160297860A1 (https=)
EP (1) EP3071232A4 (https=)
JP (1) JP2016540506A (https=)
CN (1) CN105764527A (https=)
AU (1) AU2014352891B2 (https=)
CA (1) CA2929313A1 (https=)
MX (1) MX2016006586A (https=)
WO (1) WO2015077506A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113795756A (zh) * 2019-02-08 2021-12-14 百进生物科技公司 Il-40的用途和用于检测il-40活性的方法
CN118294671A (zh) * 2024-04-01 2024-07-05 东南大学 白介素40作为生物标志物在脓毒症诊断中的应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180237800A1 (en) * 2015-09-21 2018-08-23 The Regents Of The University Of California Compositions and methods for target nucleic acid modification
CN114231611A (zh) * 2021-12-07 2022-03-25 中南大学湘雅二医院 干扰素诱导基因ifit3对b淋巴细胞活化及分化影响的研究方法
CN119309889B (zh) * 2024-12-13 2025-03-07 天津医科大学总医院空港医院 一种在eb病毒感染状态下的胸腺增生组织中免疫状态的检测方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100004172A1 (en) * 2003-04-08 2010-01-07 Khan Nisar A Compositions for mucosal and oral administration comprising hcg fragments
CN102438652A (zh) * 2008-11-12 2012-05-02 米迪缪尼有限公司 抗体制剂
CN102482667A (zh) * 2009-07-29 2012-05-30 希森美康株式会社 人的产生il-17的辅助性t细胞的检测用标记物及试剂、以及人的产生il-17的辅助性t细胞的检测方法
EP2535714A1 (en) * 2011-06-16 2012-12-19 Istituto Nazionale Di Genetica Molecolare-INGM Biomarkers for autoimmune liver diseases and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068623A1 (en) * 1997-06-16 2003-04-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20080039413A1 (en) * 2003-10-21 2008-02-14 Morris David W Novel compositions and methods in cancer
US20120213768A1 (en) * 2011-02-19 2012-08-23 Baylor Research Institute Diagnostic and Therapeutic Uses for B Cell Maturation Antigen
WO2013177533A1 (en) * 2012-05-25 2013-11-28 California Institute Of Technology Expression of secreted and cell-surface polypeptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100004172A1 (en) * 2003-04-08 2010-01-07 Khan Nisar A Compositions for mucosal and oral administration comprising hcg fragments
CN102438652A (zh) * 2008-11-12 2012-05-02 米迪缪尼有限公司 抗体制剂
CN102482667A (zh) * 2009-07-29 2012-05-30 希森美康株式会社 人的产生il-17的辅助性t细胞的检测用标记物及试剂、以及人的产生il-17的辅助性t细胞的检测方法
EP2535714A1 (en) * 2011-06-16 2012-12-19 Istituto Nazionale Di Genetica Molecolare-INGM Biomarkers for autoimmune liver diseases and uses thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113795756A (zh) * 2019-02-08 2021-12-14 百进生物科技公司 Il-40的用途和用于检测il-40活性的方法
CN113795756B (zh) * 2019-02-08 2025-02-11 百进生物科技公司 Il-40的用途和用于检测il-40活性的方法
US12590973B2 (en) 2019-02-08 2026-03-31 BioLegend, Inc. Uses of IL-40 and methods for detecting IL-40 activity
CN118294671A (zh) * 2024-04-01 2024-07-05 东南大学 白介素40作为生物标志物在脓毒症诊断中的应用
CN118294671B (zh) * 2024-04-01 2025-01-14 东南大学 白介素40作为生物标志物在脓毒症诊断中的应用

Also Published As

Publication number Publication date
CA2929313A1 (en) 2015-05-28
AU2014352891B2 (en) 2019-09-12
US20200087368A1 (en) 2020-03-19
AU2014352891A1 (en) 2016-05-19
WO2015077506A2 (en) 2015-05-28
MX2016006586A (es) 2016-08-05
EP3071232A4 (en) 2017-09-06
WO2015077506A3 (en) 2015-11-12
EP3071232A2 (en) 2016-09-28
JP2016540506A (ja) 2016-12-28
US20160297860A1 (en) 2016-10-13

Similar Documents

Publication Publication Date Title
RU2369636C2 (ru) Лиганд gitr и связанные с лигандом gitr молекулы и антитела и варианты их применения
US20110033451A1 (en) Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor
US20200087368A1 (en) Identification of a novel b cell cytokine
JP2008532493A (ja) Ｉｌ−１７ｆとｉｌ−１７ｒとの間の相互作用の特性解析
EP3468578A1 (en) Uses of il-41
JP5704722B2 (ja) 細胞接着阻害剤およびその用途
JP6029019B2 (ja) 細胞接着阻害剤、細胞増殖阻害剤、並びに癌の検査方法および検査用キット
ZA200509143B (en) GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
WO2006093337A1 (ja) 癌の予防・治療剤
JP2024522095A (ja) 抗体
Emancipator Prospects and perspectives on IgA nephropathy from animal models.
WO2025012473A1 (en) Methods for antibody production
WO2025012471A1 (en) Methods for antibody production
CN120131955A (zh) PILRα/CD99通路抑制剂及其应用
JP2008118862A (ja) Ｎｋ細胞の機能調節剤およびそのスクリーニング法
WO2008004406A1 (fr) Agent pour moduler une dégranulation des mastocytes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160713